Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Hend Khalifa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None.
Abstract (Originalsprache)
Designing novel candidates as potential antibacterial scaffolds has become crucial due to the lack of new antibiotics entering the market and the persistent rise in multidrug resistance. Here, we describe a new class of potent antibacterial agents based on a 5‐aryl‐ N 2 , N 4 ‐dibutylpyrimidine‐2,4‐diamine scaffold. Structural optimization focused on the 5‐aryl moiety and the bioisosteric replacement of the side chain linker atom. Screening of the synthesized compounds focused on a panel of bacterial strains, including gram‐positive Staphylococcus aureus strains (Newman MSSA, methicillin‐ and vancomycin‐resistant), and the gram‐negative Escherichia coli (ΔAcrB strain). Several compounds showed broad‐spectrum antibacterial activity with compound 12 , bearing a 4‐chlorophenyl substituent, being the most potent among this series of compounds. This frontrunner compound revealed a minimum inhibitory concentration (MIC) value of 1 µg/mL against the S. aureus strain (Mu50 methicillin‐resistant S. aureus /vancomycin‐intermediate S. aureus ) and an MIC of 2 µg/mL against other tested strains. The most potent derivatives were further tested against a wider panel of bacteria and evaluated for their cytotoxicity, revealing further potent activities toward Streptococcus pneumoniae, Enterococcus faecium , and Enterococcus faecalis . To explore the mode of action, compound 12 was tested in a macromolecule inhibition assay. The obtained data were supported by the safety profile of compound 12 , which possessed an IC 50 of 12.3 µg/mL against HepG2 cells. The current results hold good potential for a new class of extended‐spectrum antibacterial agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University Campus, Saarbrücken, Germany.
- German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Saarbrucken, Germany.
- School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, Cairo, Egypt.
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.
- Department of Pharmacy, Saarland University, Saarbrücken, Germany.
Förderung
- None
Zitieren
APA
Khalifa, H., Rasheed, S., Haupenthal, J., Herrmann, J., Mandour, Y. M., Abadi, A. H., Engel, M., Müller, R., Hirsch, A. K. H., Abdel-Halim, M., & Hamed, M. M. (2024). Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300656
Vancouver
Khalifa H, Rasheed S, Haupenthal J, Herrmann J, Mandour YM, Abadi AH, et al. Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300656
BibTeX
@article{Khalifa2024,
author = {Khalifa, Hend and Rasheed, Sari and Haupenthal, Jörg and Herrmann, Jennifer and Mandour, Yasmine M and Abadi, Ashraf H and Engel, Matthias and Müller, Rolf and Hirsch, Anna K H and Abdel-Halim, Mohammad and Hamed, Mostafa M},
title = {Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300656}
}
EUVIMED